Online citations, reference lists, and bibliographies.
← Back to Search

Efficacy Of Diclofenac In The Prevention Of Post-ERCP Pancreatitis In Predominantly High-risk Patients: A Randomized Double-blind Prospective Trial.

Y. K. Cheon, K. Cho, J. Watkins, L. Mchenry, E. Fogel, S. Sherman, S. Schmidt, Laura Lazzell-Pannell, G. Lehman
Published 2007 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Pancreatitis is one of the major complications of ERCP and endoscopic sphincterotomy. It has been shown that nonsteriodal anti-inflammatory drugs are potent inhibitors of phospholipase A(2), activity which is increased in pancreatitis. A previous study showed reduction of post-ERCP pancreatitis with administration of rectal diclofenac. OBJECTIVE The aim of this study was to determine whether prophylactic oral diclofenac will reduce the incidence and the severity of ERCP-induced pancreatitis, especially in high-risk patients. DESIGN Single-center, randomized, double-blinded, prospective study. SETTING Indiana University Medical Center. PATIENTS A total of 207 evaluable patients were randomized to receive either diclofenac 50 mg or placebo by mouth 30 to 90 minutes before and 4 to 6 hours after ERCP. RESULTS The groups were similar with regard to patient demographics and to patient and procedure risk factors for post-ERCP pancreatitis. The overall incidence of post-ERCP pancreatitis was 16.4%. It occurred in 17 of 102 patients in the control group (16.7%) and in 17 of 105 patients in diclofenac group (16.2%). The pancreatitis was graded mild in 9.8%, moderate in 5.9%, and severe 1.0% of the control group, and mild in 10.5%, moderate in 4.8%, and severe in 1.0% of the diclofenac group. In high-risk patients, the incidence of post-ERCP pancreatitis was 17.3%. It occurred in 18.0% (16/89) in the control group and in 17.8% (16/90) in the diclofenac group. There was no significant difference between the groups in the frequency or severity of post-ERCP pancreatitis in overall and high-risk patients; however, the power of the study was less than 45%. CONCLUSIONS Prophylactic orally administered diclofenac was not observed to affect the frequency or severity of post-ERCP pancreatitis in high-risk patients.
This paper references
10.1016/S0016-5107(04)00353-0
Prevention of post-ERCP pancreatitis: a comprehensive review.
M. Freeman (2004)
10.1016/S0016-5107(96)80486-X
Does leaving a main pancreatic duct stent in place reduce the incidence of precut biliary sphincterotomy (ES)-induced pancreatitis? a final analysis of a randomized prospective study
S. Sherman (1996)
10.1067/MGE.2001.115730
Stent placement in the pancreatic duct prevents pancreatitis after endoscopic sphincter dilation for removal of bile duct stones.
T. Aizawa (2001)
10.2165/00003088-199121020-00003
Pharmacokinetics of Rectal Drug Administration, Part II
E. J. Hoogdalem (1991)
10.1067/MGE.2003.124
Does a pancreatic duct stent prevent post-ERCP pancreatitis? A prospective randomized study.
A. Fazel (2003)
10.1016/S0016-5107(90)70958-3
Pancreatic stents can induce ductal changes consistent with chronic pancreatitis.
R. Kozarek (1990)
Inflammatory mediators and cytokines--new aspects of the pathophysiology and assessment of severity of acute pancreatitis?
V. Gross (1993)
10.1111/j.1460-9592.2004.01232.x
Diclofenac and metabolite pharmacokinetics in children
Caroline D. Marel (2004)
10.1016/S0016-5085(03)00384-6
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
B. Murray (2003)
10.1016/J.GIE.2005.11.060
A prospective, randomized, placebo-controlled trial of transdermal glyceryl trinitrate in ERCP: effects on technical success and post-ERCP pancreatitis.
A. Kaffes (2006)
10.1016/S0016-5107(04)02013-9
Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials.
P. Singh (2004)
10.1067/MGE.2002.122616
Complications of endoscopic sphincterotomy: can heparin prevent acute pancreatitis after ERCP?
T. Rabenstein (2002)
10.1055/S-2001-16520
A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis.
A. Budzyńska (2001)
10.1016/S0016-5107(05)01572-5
Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis.
P. Mosler (2005)
10.1053/gast.2001.26047
Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography.
J. Deviére (2001)
10.1067/MGE.2001.117550
Risk factors for post-ERCP pancreatitis: a prospective, multicenter study.
M. Freeman (2001)
10.1067/MGE.2003.29
Transdermal glyceryl trinitrate for prevention of post-ERCP pancreatitis: A randomized double-blind trial.
M. Moretó (2003)
10.1046/J.0007-1323.2001.01842.X
Prospective randomized double‐blind placebo‐controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography‐induced pancreatitis
S. Sudhindran (2001)
10.1016/S0016-5085(98)70031-9
Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction.
P. Tarnasky (1998)
10.1016/S0016-5107(05)00653-X
Efficacy of Recombinant Human Interleukin-10 in Prevention of Acute Pancreatitis After ERCP in Subjects with Increased Risk: Randomized Prospective Multicenter Study
S. Sherman (2005)
10.1067/MGE.2003.307
Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study.
S. Sherman (2003)
10.1055/S-2002-23629
Sphincter of Oddi dysfunction: pancreaticobiliary sphincterotomy with pancreatic stent placement has a lower rate of pancreatitis than biliary sphincterotomy alone.
E. Fogel (2002)
10.1016/S0016-5107(04)00159-2
Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis.
T. Rabenstein (2004)
10.1136/gut.29.7.926
Allopurinol attenuates caerulein induced acute pancreatitis in the rat.
J. Wisner (1988)
10.1016/S0002-9270(01)02655-7
A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis
J. Dumot (2001)



This paper is referenced by
10.1016/j.surge.2013.10.010
Rectal NSAIDs for the prevention of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials.
Hongli Sun (2014)
10.1016/j.gie.2011.04.047
Use of udenafil is not associated with a reduction in post-ERCP pancreatitis: results of a randomized, placebo-controlled, multicenter trial.
Hyoung-Chul Oh (2011)
10.1016/j.gie.2016.06.051
Adverse events associated with ERCP.
V. Chandrasekhara (2017)
10.1007/s10620-016-4251-x
No Benefit of Oral Diclofenac on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
Hirotoshi Ishiwatari (2016)
Comparative study between transdermal Glyceryl Trinitrate, Octreotide, and Diclofenac injection in the prevention of post-ERCP pancreatitis
E. Nashaat (2010)
10.1016/j.gie.2017.01.033
Indomethacin and diclofenac in the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis of prospective controlled trials.
Á. Patai (2017)
10.1053/j.gastro.2016.02.090
Appropriate Timing of Rectal Indomethacin Administration and Patient Selection in Assessment of Post-ERCP Pancreatitis.
R. Dong (2016)
10.1371/journal.pone.0092922
How and When Should NSAIDs Be Used for Preventing Post-ERCP Pancreatitis? A Systematic Review and Meta-Analysis
I. Puig (2014)
10.12691/AJCMR-2-2-1
Diclofenac vs. Placebo in a Randomized Double Blind Controlled Trial, in Post ERCP Pancreatitis
Yasser Abu-Safieh (2014)
10.1016/J.TGIE.2014.05.003
Pharmacologic prevention of pancreatitis after endoscopic retrograde cholangiopancreatography: Present and future
B. Elmunzer (2014)
10.1038/nrgastro.2012.121
Hepatitis: Hepatitis E and decompensated chronic liver disease
H. Dalton (2012)
10.4166/KJG.2012.60.4.270
Could Rectally Administered Indomethacin Reduce the Incidence of Post-ERCP Pancreatitis?
Sang-Woo Cha (2012)
10.5772/26137
Endoscopic Retrograde Cholangiopancreatography (ERCP) Related Acute Pancreatitis
Z. Döbrönte (2012)
10.6092/1590-8577/2258
The role of nonsteroidal anti-inflammatory drugs in the prevention of post endoscopic retrograde cholangiopancreatography pancreatitis.
I. Sheikh (2014)
10.5348/IJHPD-2015-42-OA-17
Role of rectal diclofenac suppository for prevention and its impact on severity of post-ERCP pancreatitis in high risk patients
S. Patil (2015)
10.1186/s12876-018-0837-4
What is impact of nonsteroidal anti-inflammatory drugs in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials
Yunxiao Lyu (2018)
10.1097/MPA.0b013e31819777d5
Efficacy of Recombinant Human Interleukin-10 in Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis in Subjects With Increased Risk
S. Sherman (2009)
ИСПОЛЬЗОВАНИЕ НЕСТЕРОИДНЫХ ПРОТИВОВОСПАЛИТЕЛЬНЫХ ПРЕПАРАТОВ ДЛЯ ПРОФИЛАКТИКИ ОСТРОГО ПАНКРЕАТИТА ПОСЛЕ ЭНДОСКОПИЧЕСКОЙ РЕТРОГРАДНОЙ ХОЛАНГИОПАНКРЕАТОГРАФИИ (ОБЗОР ЛИТЕРАТУРЫ)
E. V. Moroz (2015)
10.4103/AZMJ.AZMJ_22_19
Role of rectal NSAID administration time in prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis
Z. Zakarya (2020)
Identificando los factores de riesgo para pancreatitis postcolangiopancreatrografía endoscópica, un estudio prospectivo
Jesús Carrasco (2012)
10.14312/2399-8199.2016-2
The incidence of post-ERCP pancreatitis is not reduced in patients given intravenous ketorolac for post-procedural abdominal pain
A. Mariani (2016)
Efficacy of Postprocedure Administration of Parecoxib Sodium in the Prevention of Post-ERCP Pancreatitis
(2009)
10.3748/WJG.15.3999
Efficacy of intramuscular diclofenac and fluid replacement in prevention of post-ERCP pancreatitis.
Altuğ Şenol (2009)
10.3748/wjg.v22.i21.5114
Suppository naproxen reduces incidence and severity of post-endoscopic retrograde cholangiopancreatography pancreatitis: Randomized controlled trial.
F. Mansour-Ghanaei (2016)
10.3904/kjim.2015.30.5.602
Oral udenafil and aceclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a randomized multicenter study
T. Y. Lee (2015)
10.1097/MPA.0000000000000326
Factors Affecting the Efficacy of Nonsteroidal Anti-inflammatory Drugs in Preventing Post–Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Systematic Review and Meta-analysis
T. Rustagi (2015)
10.1016/j.giec.2014.09.006
Endoscopic retrograde cholangiopancreatography (ERCP)-related adverse events: post-ERCP pancreatitis.
T. Rustagi (2015)
10.1007/s11377-014-0873-8
Komplikationen nach ERCP
T. Rabenstein (2014)
10.3109/00365521.2016.1172338
Effect of body weight on fixed dose of diclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis
Bonna Leerhøy (2016)
10.1007/s11938-018-0194-y
Update on the Prevention of Post-ERCP Pancreatitis
H. Zhang (2018)
10.1097/MPA.0b013e3181dc67e7
Role of Ulinastatin in Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: The Emperor's New Clothes or Aladdin's Magic Lamp?
Suyu Chen (2010)
10.1097/01.mpg.0000361657.54810.19
Post-ERCP Pancreatitis in Pediatric Patients
C. Iqbal (2009)
See more
Semantic Scholar Logo Some data provided by SemanticScholar